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Abstract
22q11 Deletion Syndrome (22q11DS) is associated with dysmorphology and a high prevalence of schizophrenia-like
symptoms. Several genes located on chromosome 22q11 have been linked to schizophrenia. The deletion is thought to
disrupt the expression of multiple genes involved in maturation and development of neurons and neuronal circuits, and
neurotransmission. We investigated whole-genome gene expression of Peripheral Blood Mononuclear Cells (PBMC’s) of 8
22q11DS patients and 8 age- and gender-matched controls, to (1) investigate the expression levels of 22q11 genes and (2)
to investigate whether 22q11 genes participate in functional genetic networks relevant to schizophrenia. Functional
relationships between genes differentially expressed in patients (as identified by Locally Adaptive Statistical procedure (LAP)
or satisfying p,0.05 and fold-change .1.5) were investigated with the Ingenuity Pathways Analysis (IPA). 14 samples (7
patients, 7 controls) passed quality controls. LAP identified 29 deregulated genes. Pathway analysis showed 262 transcripts
differentially expressed between patients and controls. Functional pathways most disturbed were cell death, cell
morphology, cellular assembly and organization, and cell-to-cell signaling. In addition, 10 canonical pathways were
identified, among which the signal pathways for Natural Killer-cells, neurotrophin/Trk, neuregulin, axonal guidance, and
Huntington’s disease. Our findings support the use of 22q11DS as a research model for schizophrenia. We identified
decreased expression of several genes (among which COMT, Ufd1L, PCQAP, and GNB1L) previously linked to schizophrenia
as well as involvement of signaling pathways relevant to schizophrenia, of which Neurotrophin/Trk and neuregulin signaling
seems to be especially notable.
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Introduction
Deletions of chromosome 22q11 are associated with a high
prevalence of dysmorphology (velo-cardio-facial syndrome;
22q11DS), cognitive and behavioural disorders and schizophre-
nia-like psychosis [1,2]. It is thought that a hemizygous 22q11
deletion disrupts the expression of multiple genes involved in
maturation, development of neurons and neuronal circuits, and
neurotransmission [3]. Several genes located in the 22q11 region
have been linked to schizophrenia, including COMT, ProDH,
Ufd1L, PCQAP [4], and, recently, GNB1L [5]. It is likely that
genes present in the 22q11 deleted region form functional
networks (i.e. metabolic-and signaling pathways) with other genes
outside this region involved in development and neuronal
functioning, and that the decreased expression of 22q11 genes
alters the functional activity of these pathways. It is however
unclear which pathways these are, and what their relationship is
with pathways involved in idiopathic schizophrenia. More insight
into the nature of these functional networks may increase our
understanding in the genetic networks involved in the develop-
mental, psychiatric, cognitive and behavioural disturbances seen in
22q11DS including schizophrenia. Moreover, it will provide more
understanding of the relationship between 22q11DS and schizo-
phrenia and the value of 22q11DS for investigating schizophrenia
pathology.
The combination of gene expression profiling and biomics is
proven to be a powerful technology to identify functional changes
in genetic networks [6]. However, for neuropsychiatric disorders a
major limitation is the inaccessibility of the living brain and the
heterogeneity of many psychiatric disorders. This is especially
relevant for disorders such as schizophrenia, which show a
prolonged life-long course during which the effects of normal and
abnormal brain development, drug abuse and medication
influence the results of post-mortem gene-expression studies
[6,7]. Peripheral Blood Mononuclear Cells (PBMC’s) express
many brain relevant genes [8] and have been suggested as
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‘window-on-the brain’ surrogate tissue to investigate neuropsychi-
atric disorders. In schizophrenia, a number of recent studies have
explored the use of various types of PBMC’s [9–13]. The key
assumption of these studies is that although peripheral blood cells
in schizophrenia show no clear aberrations in function or
morphology, subtle molecular-biological aberrations are present
and can be informative about the molecular-biological underpin-
nings of schizophrenia. However, in non-22q11DS schizophrenia
a multivariate genetic and environmental cause is suspected.
Therefore PBMC gene expression of patients with idiopathic
schizophrenia may be largely variable. We reasoned that in
22q11DS the deletion will most likely result in decreased PBMC
expression of 22q11 genes which may in turn influence the
expression of other genes outside the deleted region more robustly
and persistently than in idiopathic schizophrenia. Furthermore,
using functional pathway analysis, 22q11DS might offer a view of
the concerted altered expression of genes both within and without
the 22q11 deleted region that may alter the activity of functional
genetic networks.
PBMC gene expression in 22q11DS patients has not yet been
investigated, neither the individual expression levels of genes in the
22q11 deleted region, nor the influence of the deletion on
functional genetic pathways. Thus, we investigated gene expres-
sion in PBMC’s of 22q11DS patients, with the objective to (1)
investigate the expression levels of 22q11 genes and to (2)
investigate whether 22q11 genes, together with genes outside this
region, participate in functional networks relevant for (neuro)de-
velopmental abnormalities in 22q11DS.
Materials and Methods
Subjects
8 22q11DS patients and 8 age-and gender matched controls
were included in this study. Deletions at chromosome 22q11 were
previously identified in all subjects by Fluorescence In-Situ
Hybridization (FISH). This study was approved by the institu-
tional review boards of the two participating centres (Erasmus
University Medical Centre, Rotterdam, and Academic Medical
Centre, Amsterdam) and was performed in accordance with the
declaration of Helsinki. All subjects provided written informed
consent.
Samples
From each participant 30 ml of blood was drawn into
heparinized tubes. PBMC’s were isolated by Ficoll-gradient
separation starting 90 minutes after the drawing of blood. Cells
were subsequently disrupted (Qiashredder kit; Qiagen), and RNA
was isolated (RNeasy minikit; Qiagen) with an additional DNAse
digestion step (RNase-free DNase set; Qiagen), all according to the
manufacturer’s protocol, diluted in nuclease free water and frozen
at 280 C before use. After thawing the isolated RNA was
biotinylated into cRNA using the One-Cycle Target Labeling and
Control Reagents Kit (Affymetric Co) according to the manufac-
turer’s protocol. Before hybridization RNA quality and integrity
was assessed using the Agilent 2100 BioAnalyzer (Agilent) and
RNA purity and quantity with the NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies). Biotinylated cRNA
was hybridized to the Affymetrix Human Genome U133 plus 2.0
GeneChip microarray containing 54,675 probe sets (Affymetrix
Co). Each sample was individually biotinylated and hybridized to
an individual microarray. Biotinylation was performed in two
batches with randomization of samples across the batches.
Hybridization was performed in one batch. The arrays were
scanned and analyzed using Affymetrix Microarray Suite 4.2
software.
Statistical analysis
Probe sets that were absent in all samples (according to
Affymetrix software) were omitted from further analysis. Raw
intensities (33,196 probe sets) were normalized by quantile
normalization. Data analysis was done using OmniViz version 5.0
(Biowisdom) and R program. Minimum thresholds were set at 30.
To investigate the expression levels of genes in the 22q11 region
between patients and controls we applied two separate methods,
Significance Analysis of Microarrays (SAM) [14] (OmniViz) and
Locally Adaptive Statistical procedure (LAP) [15] (R program).
SAM uses permutations of the repeated measurements of the
expression levels to estimate the false discovery rate (FDR). LAP
combines a FDR approach with information about chromosomal
location of the genes and is specifically suited to identify
differentially expressed regions that are involved in known
chromosomal aberrations [15]. It should be noted that LAP may
identify significantly decreased expression of genes which are
actually not expressed at all, due to way the LAP algorithm uses
information about chromosomal location. These not expressed
genes were removed from further analyses. To investigate the
functional relationships between genes which are differentially
expressed between patients and controls we used the Ingenuity
Pathway Analysis (IPA) (Ingenuity SystemsH; www.ingenuity.com;
October 2007). The IPA is an internet-accessible database in which
knowledge about the interaction between genes and gene products
is stored based on known interactions in the literature [16]. Thus,
the IPA defines genetic networks, functions, and metabolic-and
signaling pathways which describe functional relationships between
gene products and presents as output networks, functions and
metabolic-and signaling pathways in which the genes in the dataset
participate more than can be expected by change. It does so by
calculating a significance score (using the right-tailed Fisher’s exact
test and expressed as a p-value) for each process by computing the
number of deregulated genes that participate in a network or
pathway relative to the total number of occurrences of these genes in
all functional/pathway annotations stored in the IPA. The
significance value associated with networks and pathways is a
measure for how likely it is that genes from a dataset participate in
that function or pathway. For genetic networks an IPA score.=3 is
considered significant, for canonical pathways a p-value,.05 is
considered significant. We uploaded into the IPA a dataset which
consisted of the genes identified by LAP and of genes with different
expression levels between patients and controls according to the
criteria: t-test between patients and controls significant (p,0.05)
and a 1.5 or more fold-change (FC) in expression level in patients
compared to controls.
Results
Subjects
8 22q11DS patients and 8 controls were included. Four patients
had a previous history of psychotic symptoms, whereas four did
not (further characteristics see table 1).
Routine quality controls of the gene expression results showed
sub-optimal signal-to-noise ratios in two subjects (one patient with
psychosis and one control). These two samples were excluded from
further analyses.
Global significance analysis of gene expression
SAM showed 14 transcripts differentially expressed between
patients and controls (False Discovery Rate (FDR) = 6.6%; falsely
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called,1) (see table 2). Ten of these transcripts are located in the
22q11 region.
LAP identified 44 genes (p value,0.05), all in the 22q11 region
(see figures 1 and 2).
Of these 44 genes, 9 were not expressed in blood and 6 were not
differentially expressed between patients and controls, resulting in
29 differentially expressed genes.
Pathway analysis
The criteria p,0.05 and FC.1.5 showed 262 transcripts
differentially expressed between patients and controls. These 262
transcripts are described in table S1. Combining these with the
genes identified by LAP (n= 29) and uploading these in the IPA
generated 128 genes available for building networks and
investigating relationships. Seven functional networks are consid-
ered to be significantly associated with the uploaded gene set
according to IPA criteria (IPA score.3) These networks are
involved in (among others) cardiovascular disease, cardiovascular
system development and function, nervous system development
and function, connective tissue development and function, cell
signaling, and cell-to-cell signaling and interaction. Table 3 shows
the seven highest ranking networks, and the biological processes
associated with these networks.
Canonical pathways identified by the IPA in which the
uploaded gene set participates more than can be expected by
chance (p,.05) are Natural Killer (NK)-cell signaling (p = .0004),
neurotrophin/Trk signaling (p = .003), Fibroblast Growth Factor
(FGF) signaling (p = .006), leukocyte extravasation signaling
(p = .007), neuregulin signaling (p= .002), complement and
coagulation cascades (p = .002), Platelet Derived Growth Factor
(PDGF) signaling (p = .003), ERK/MAPK signaling (p = .003),
axonal guidance signaling (p = .047), and Huntington’s disease
signaling (p= .049).
Comparison of PBMC expression levels with brain
expression levels in mouse models
The Df1/+ heterozygous mice (Df1/+), a model for 22q11DS,
displays specific deficits in hippocampus-dependent functions.
Sivagnanasundaram et al [17] analyzed the hippocampal gene
expression of genes mapping to the deleted region as compared to
wild type (WT) mice. Twelve genes were differentially expressed in
the hippocampus. Of these twelve genes seven were also expressed
in our PBMC samples (DGCR6, RANBP1, ZDHHC8, HTF9C,
COMT, CLDN5, and UFD1L). The relative expression levels of
these genes (hippocampal levels of Df1/+ vs WT mice (after
Sivagnanasundaram et al [17]) and PBMC levels of 22q11DS
patients vs controls) are shown in table 4.
The relative expression levels of mice and humans correlated
strongly and significantly (r: 0.677, p= 0.05, one sided). In another
study, Meechan et al [18] investigated the expression levels of nine
22q11 orthologues in a 22q11DS mouse model (IDD, PRODH2,
ZDHHC8, RANBP1, T10, COMT-MB, TBX1, UFD1L, and
HIRA) in the developing and adult mouse brain. They also found
diminished expression for the entire set of orthologues. Their
findings indicated a fairly consistent decrease in expression levels
with a magnitude between 40% and 60%, quite similar to our
PBMC findings. Taken together, these results in mice cautiously
suggest that diminished expression levels of 22q11 genes in PBMC’s
in humans might reflect decreased expression levels in the mouse
brain for those genes which are also expressed in neuronal tissue.
Table 1. Subject characteristics.
Pair # PATIENTS CONTROLS
Psychosis Antipsychotic use Age gender Age gender
1 No none 18 F 19 F
2 No none 39 F 39 F
3 No none 25 M 25 M
4 No none 17 F 18 F
5 Yes zuclopentixole 27 M 27 M
6 yes* risperidone 32 F 30* F
7 Yes risperidone 25 M 26 M
8 Yes risperidone 21 M 21 M
*excluded cases (N = 2) because of bad signal-to-noise ratio of the expression
data; coincidentally, the excluded cases form a matched pair.
doi:10.1371/journal.pone.0033473.t001
Table 2. Significance Analysis of Microarrays (SAM).
Probe Set ID Gene Title Gene Symbol Entrez Gene Chromosomal Location
229906_at Armadillo repeat containing 7 ARMC7 79637 chr17q25.1
217427_s_at HIR histone cell cycle regulation defective homolog A (S. cerevisae) HIRA 7290 chr22q11.2| chr22q11.21
1553974_at Hypothetical protein 1 LOC128977 128977 chr22q11.2
202483_s_at RAN binding protein 1 RANBP1 5902 chr22q11.2
203152_at Mitochondrial ribosomal protein L40 MRPL40 64976 chr22q11.2
209103_s_at Ubiquitin fusion degradation 1 like (yeast) UFD1L 7353 chr22q11.2
210010_s_at Solute carrier family 25 (mitochondrial carrier; citrate transporter), member 1 SLC25A1 6576 chr22q11.2
32032_at DiGeorge syndrome critical region gene 14 DGCR14 8220 chr22q11.2| chr22q11.2
208818_s_at Catechol-O-methyltransferase COMT 1312 chr22q11.2-q11.23
206184_at v-crk sarcoma virus CT10 oncogene homolog (avian)-like CRKL 1399 chr22q11.2| chr22q11.21
212180_at v-crk sarcoma virus CT10 oncogene homolog (avian)-like CRKL 1399 chr22q11.2| chr22q11.2
202206_at ADP-ribosylation factor-like 4C ARL4C 10123 chr2q37.1
235289_at Eukaryotic translation initiation factor 5A2 EIF5A2 56648 chr3q26.2
230685_at Hypothetical protein LOC644873 FLJ33630 644873 chr5q23.3
doi:10.1371/journal.pone.0033473.t002
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Discussion
To our best knowledge our study is the first to examine gene
expression of 22q11DS patients. We show decreased expression of
several genes present in the 22q11 deleted region. Among these
are the genes which have been previously associated with
schizophrenia, COMT, Ufd1L, PCQAP [4], and GNB1L [5].
Canonical pathway analyses show the significant involvement of
the canonical pathways NK-cell signaling, neurotrophin/Trk
signaling, FGF signaling, leukocyte extravasation signaling,
neuregulin signaling, complement and coagulation cascades,
PDGF signaling, ERK/MAPK signaling, axonal guidance signal-
ing, and Huntington’s disease signaling. The phenotypical
expression of 22q11DS is highly variable. Among the major
phenotypic features encountered are, apart from schizophrenia,
cardiac anomalies, immunodeficiencies, craniofacial defects,
hypocalcaemia, as well as a broad range of other psychiatric,
cognitive and behavioral problems [19]. The most significantly
involved canonical pathway in our study is NK-cell signaling.
Immunodeficiency is one of the key features of 22q1DS, occurring
secondary to thymic aplasia or hypoplasia with subsequent
impaired thymocyte development. The majority of patients
present with low or absent T-lymphocytes, but with spared B-
lymphocytes and NK cells. An increased proportion of NK-cells
have been described in patients with 22q11DS [20–22].However,
the spectrum of severity of the immune deficit varies widely and
does not appear to be related to other phenotypic abnormalities
[23].Altered NK-cell activity in idiopathic schizophrenia has been
reported in some studies [24] and is hypothesized to be related to
the altered immunity and the reduced occurrence of autoimmune
diseases and malignancies that has been observed in schizophrenia
[25]. However, generally there is no clear agreement among
Figure 1. Results of the Locally Adaptive Statistical Procedure (LAP). Green rows show genes which are not expressed in PBMC’s; red rows
show genes not differentially expressed in PBMC’s between patients and controls. Columms respectively show (from left to right): Probe Set ID; Entrez
Gene ID; Gene Symbol; SAM score (di); smoothed score (Si); chromosomal localization and position; qvalues; median intensity of the controls (CO);
median intensity of the 22q11DS patients; ratio 22q11DS/CO and log2 ratio 22q11DS/CO.
doi:10.1371/journal.pone.0033473.g001
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studies on the involvement of NK cell activity in schizophrenia,
with some studies showing lower activity, some higher activity, and
the majority no change in activity between schizophrenia patients
and controls [24]. Alterations in NK signaling as observed in our
patient sample may be related to these previously reported
immune deficits; however, it should be kept in mind that the
finding of immune perturbations could also be a confounding
epiphenomenon of the specific tissue under investigation.
There is far more support for the involvement of neurotrophin/
Trk signaling in schizophrenia. This pathway is activated via the
Trk family of receptors by various neurotrophic factors. The
neurotrophic factors best known for their association with
schizophrenia are Brain-derived Neurotrophic Factor (BDNF),
Nerve Growth Factor (NGF), and neurotrophin-3 (NT-3). BDNF,
NGF, and NT-3 are involved in a range of neuroplastic processes.
Disturbed neurotrophin signaling is thought to underlie the
neurodevelopmental disturbances seen in schizophrenia. Altered
brain-(reviewed in Shoval and Weizmann [26]) and serum levels
(reviewed in van Beveren et al ([27]) of neurotrophins have
repeatedly been reported in schizophrenia.
There is also considerable support for an association of
neuregulin with schizophrenia. Neuregulin is considered one of
the genes most strongly associated with schizophrenia [28–30].
Neuregulin has been implicated in neuronal differentiation and
migration. However, no consistent changes in neuregulin
expression have been detected in schizophrenia. A recent report
has shown that genetic variation in neuregulin (NRG1) is
associated with variance in white matter brain content in normal
individuals [31], as investigated by magnetic resonance imaging.
Barnes et al [31] showed that genetic variation in the neuregulin
variant SNP8NRG243177 is associated with variation in frontal
brain structure in both grey and white matter. Reduced global
white matter, most prominently in posterior and temporal regions,
has been reported in 22q11DS [32–34]. So, altered neuregulin
signaling as observed in our 22q11DS sample may be related to
dysmaturation of white matter. Disturbances in axonal guidance
signaling and Huntington’s disease signaling are at present not
specifically associated with schizophrenia but may underlie the
general cognitive and behavioural disturbances found in schizo-
phrenia. Moreover, in 22q11DS frequently motor disturbances,
obsessive-compulsive symptoms, tics, and neurological aberrations
are being observed [25], which are also found in Huntington’s
disease, and recent studies suggest that cognitive deterioration in a
22q11DS may already start in childhood [35], with a dramatic
cognitive decline in adulthood in some psychotic 22q11DS
patients.
There is an interesting possible relationship between
22q11DS and FGF signaling. Aggarwal et al [36] and Guo et
al [37] described epistatic relationships between the FGF system
and Tbx1. It is firmly established that Tbx1 is responsible for
most of the congenital defects seen in 22q11DS patients and
mouse models [38–40]. Tbx1 point mutations were found in
patients who displayed the key physical symptoms of the classic
22q11DS phenotype, but did not have a 22q11 deletion [41].
There is incidental evidence for an association of FGF signaling
with idiopathic schizophrenia. One publication reports de-
creased serum levels of FGF in schizophrenia [42,43]. We could
not identify reports describing involvement of PDGF signaling
in schizophrenia. However, both FGF and PDGF are important
growth factors of which involvement in schizophrenia has been
suggested on theoretical grounds [30]. Disturbances in leucocyte
extravasation signaling, and complement and coagulation
Figure 2. Expression levels of genes in the 22q11 deleted region. The figure shows the ratio of the median expression levels of patients
versus controls for each of the genes shown along the x-axis.
doi:10.1371/journal.pone.0033473.g002
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cascades cannot be clearly related with 22q11DS and schizo-
phrenia pathology. It has been postulated that subtle aberrations
in cellular machinery may be present in all organs and cell types
in schizophrenia [44], but only give rise to overt pathology in
the nervous system. Such subtle aberrations may however
become present in in-vitro situations, explaining differences in
coagulation and leucocyte functions between patients and
controls.
Taken together, our pathway analyses show a number of
pathways previously associated with idiopathic schizophrenia
among the pathways significantly associated with the deregulated
gene set in our 22q11DS sample. Most notably for their
involvement in schizophrenia are neurotrophin/Trk signaling
and neuregulin signaling. Our findings cautiously suggest that the
molecular-biological underpinnings of the psychotic phenomena
observed in 22q11DS are at least partly related with those seen in
‘regular’ schizophrenia. Moreover, our findings are present even
though only three patients show psychotic phenomena, and four
do not. This suggests that molecular-biological pathways involved
schizophrenia are deregulated in 22q11DS patients both with and
without psychosis, and that, like in idiopathic schizophrenia,
environmental factors modulate the expression of the psychosis
phenotype in 22q11DS. Furthermore, the psychiatric phenotype
in 22q11DS is extremely variable, and besides schizophrenia a
range of other (neuro)psychiatric disorders, including autism
spectrum disorders, mood disorder, attention deficit hyperactivity
Table 3. Significantly deregulated genetic networks as identified by the Ingenuity Pathways Analysis (IPA).
ID Molecules in Network Score
# of Focus
Molecules Top Functions
1 ARNT2, B2M,qBASP1,QCDC42, CYBA, H2-Q1, HLA-E, JAK2,qKCNJ15, KLRC1,
QKLRC2,QKLRC3,QKLRD1,qMEF2C,qMXD1, MYCN, PAK1,QPARD6A,
PARD6G,QPIK3R3,qPPM1F,QPTPN4, QDM, RAC2,QRANBP1, Rb, RB1, RBL2,
QSEPT5,QSNAP29,qSNX5, STX1A,qSTXBP2,qTLR4, VAMP2
26 18 Cell Cycle, Connective Tissue
Development and Function, Nervous
System Development and Function
2 QACVR2B,QCD2,QCOMT, CRK,QCRKL,QCXCL10,qDDEF1,qDOCK4,
E2F4, EPHB6, ESR1,qETV6,QEXOSC2, EXOSC7, EXOSC8, EXOSC9, EXOSC10,
qHSF1, Hsp70, HSPA7,qMAFG, MAP4K5, MYC, NFE2L3,QNQO1,qP2RX1,
qPCID1, PIK3R1, PLAG1,QPPP2R2B, RICS,qSENP6,qSLC11A1, SUMO1, XRN2
24 17 Cancer, Hematological Disease,
Cell-To-Cell Signaling and
Interaction
3 APEX1, ATF3, CARM1,QCCL5, CCR4,qCD24, CD63, CKM,QCPT1A,
QDGCR6, EP300,qGK,qHK2, MDM2 (includes EG:4193),QMYO6,
NEUROG3,qOLIG1,QPIK4CA, PPARGC1A,QPRF1, PTGDS,QPYHIN1,
RELA, SELP, SLC2A4,qSLC2A5,QTBX21, TFDP1,qTNFRSF10C, TP53,
TRIM28, TSC22D3, ZBTB17,QZDHHC8,QZNF74
22 16 Gene Expression, Cancer,
Respiratory Disease
4 qABCA1,QAPI5, CDKN2A, CKB,qCR1, CR2,Q4S234E,QDGCR14, DLG4,
QF2R, FGF2, FLT1,QGZMA, HMGB2,qHPSE, Hsp27, KCNJ4, KCNJ12, KPNB1,
LAMA1,qLIN7A,qNAB2,QPCQAP, RNA polymerase II,QRNGTT, RNMT, SMAD3,
Smad2/3, SP1, STX12, SUPT5H,qTFE3,QUFD1L,QZNF83,qZNF451
22 16 RNA Post-Transcriptional
Modification,
Cell Signaling, Cardiovascular
System Development and Function
5 qADAM9 (includes EG:8754), APOB,QAPOBEC3G,QARL4C, CEBPA, CIAA1,
CIAA2, COL10A1, COL11A2, COL18A1, COL1A1, COL2A1, COL3A1,QCOL5A3,
qCSF2RA, EGR2, GRM5,qHES7, HMGB2, Homer, HOMER1, HOMER3,qHP, ITGA2,
ITGA9 (includes EG:3680), ITGB1, ITPR, NFYB, NFYC,qPTPRE, SHANK3,qTHBD,
qTNFRSF8,QTXNRD2,qZBTB7B
17 13 Dermatological Diseases and
Conditions, Cardiovascular
Disease, Cell Cycle
6 qAQP9, ARF1, CARM1, CBX1, CBX5,qCD53,QCENTG2,QCHAF1A, Creb,
qCREB5, CREM,qERAF, GRIA2, GRM7, H3F3B,QHIRA, HIRIP3, Histone h3, KIR3DL1,
MBD1, NCAPD2, NCOA1, NCOA2, PICK1, Pkc(s), PLD1,qPRKCA,QRORA,QRORC
(includes EG:6097), SETDB1, SFTPA1,QSMC2, SMC4,QTHAP7, TRIM24
15 12 Cell-To-Cell Signaling and
Interaction, Nervous System
Development
and Function, Cell Morphology
7 qACSL4, Actin, Arp2/3,qBACH2 (includes EG:60468),QC19ORF12,
CAM, CD44,QCLDN5,QCLDN19,QCLIC5, DNMBP, HDAC4, MARK4
(includes EG:57787), NCOR2, PARD3,QPARD6A, PARD6B, PARD6G,
qPDK1, PFN1,QPHLDB2, PKC (l,f), PRKCI,qRAPGEF2, SMARCA4,
STK11, TJP1, TJP2, TJP3, VIM, WAS,qWASF1, WASF2, YWHAQ, YWHAZ
13 11 Cell Morphology, Cellular
Development, Cell-To-Cell
Signaling and Interaction
The table displays the seven functional networks identified by the IPA as significantly (score.3) associated with the geneset defined by the two critera (1) deregulated
between patients and controls according to LAP or (2) t-test,0.05 and Fold Change.1.5. The table displays the genes associated with the functional networks (genes
which are present in the uploaded gene set are in bold). The arrows behind a gene indicate the direction of change (arrow pointing upwards: increased expression in
patients, arrow pointing downwards: decreased expression in patients).The column ‘score’ gives the significance score for the network. The column ‘# of genes’ gives
the number of genes in the network. Each network consists –by definition of the IPA- of 35 genes. The last column shows the functions in which each network is
predominantly involved.
doi:10.1371/journal.pone.0033473.t003
Table 4. Relative hippocampal gene expression levels.
Gene
Relative hippocampal
expression Df1/+ vs WT
Relative PBMC expression
22q11DS patients vs controls
DGCR6 0.45 0.49
RANBP1 0.53 0.40
ZDHHC8 0.86 0.63
HTF9C 0.63 0.47
COMT 0.54 0.54
CLDN5 0.68 0.56
UFD1L 0.78 0.52
The table dispays the relative hippocampal expression levels of Df1/+ vs WT
mice (after Sivagnanasundaram et al, 2007 [17]) and PBMC gene expression
levels of 22q11DS patients vs controls (this study) for seven genes expressed in
both samples (mice and humans).
doi:10.1371/journal.pone.0033473.t004
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disorder, developmental delay, and learning disabilities. The co-
occurrence of various psychiatric phenomena in 22q11DS may be
an example where a general genetic vulnerability for mental
impediments leads to variable phenotypic expression, probably
dependent on (time-critical) environmental and stochastic influ-
ences. It is tempting to ascribe the other mental disorders present
in 22q11DS to alterations in signaling pathways related to
neuronal functioning, and/or pathways known to be disturbed
in neuropsychiatric syndromes, such as axonal guidance signalling
and Huntington’s disease signalling, neuregulin signalling, and
neurotrophin signalling. One may speculate that in the 22q11DS
alteration in several distinct functional signaling cascades are
present early on in life, with alterations in these cascades becoming
more or less prominent, depending on environmental influences,
and epistatic interaction with present or absent variants of risk
genes outside the 22q11 deleted region.
Our study has a number of limitations; first, the number of
subjects is small and heterogeneous (i.e. with-and without
psychosis). Second: to identify functional networks we used a
liberal statistical approach by not correcting for repeated
measurements to obtain the gene set with criteria p,0.05 and
FC.1.5, with a risk of identifying false-positives. However, we
assume that combining this set with the genes present in the 22q11
deleted region (the set identified by LAP), which are certainly no
false-positives, and investigating the functional relationships of
combined gene set will ‘pull out’ the true positive genes as those
will be the ones that predominantly have functional relationships
with the 22q11 genes. Not so much a limitation as well as a caveat
is that the approach presented here (investigating PBMC gene
expression to gain insight in neuropsychiatric phenomena) relies
on the assumption that molecular-biological aberrations observed
in peripheral tissue can be informative about brain molecular-
biological processes. Though may signaling pathways are similar
in peripheral tissue and brain, and there are some reports that this
approach is feasible [8,45], the precise validity of this assumption
remains to be further elucidated. In summary, this study (1) shows
decreased expression of genes in the 22q11 deleted region in
PBMC’s of 22q11DS patients and (2) suggests the presence of
deregulated signaling pathways relevant for schizophrenia pathol-
ogy in PBMC’s of 22q11DS patients. Generally, our findings
support the use of the 22q11DS as a suitable, more homogeneous
research model for schizophrenia. A prominent feature of both
22q11DS and schizophrenia is that they have a clear develop-
mental aspect. Clinical features, including cognitive deficits and
psychotic phenomena develop over the life span. Symptoms are
thought to arise in genetically vulnerable individuals in interaction
with environmental, epistatic, and stochastic processes. This aspect
of 22q11DS may be highly relevant for the idiopathic schizophre-
nia syndrome. Approximately 30% of children with a microdele-
tion of 22q11 will develop a form of schizophrenia that clinically
and neurocognitively cannot be distinguished from the idiopathic
disorder. Important insights into the trajectory from risk to
disorder in idiopathic schizophrenia may be gained from ongoing
longitudinal studies of these children comparing cognitive,
affective and neural development in those who do and do not
develop psychosis among this cohort with a similar genomic
deletion [46]. Thus, future research in this field should
longitudinally investigate PBMC gene expression in relationship
with the phenotypical expression of symptoms in a larger sample
of young 22q11DS patients.
Supporting Information
Table S1 Full list of transcripts (N=262) differentially
expressed between patients and controls (p,0.05 and
Fold Change.1.5). Columns show (from left to right):
Affymetrix Probe Set ID; Gene Abbreviation; Chromosomal
location; log-transformed ratio of gene expression patients/
controls; significance (not corrected for multiple comparisons:
see text methods).
(XLS)
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